<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928939</url>
  </required_header>
  <id_info>
    <org_study_id>2016-00525</org_study_id>
    <nct_id>NCT02928939</nct_id>
  </id_info>
  <brief_title>Therapeutic Conflicts and Multimorbidity</brief_title>
  <official_title>Therapeutic Conflicts in Hospitalized Patients: Retrospective Analyses of Patients With GI Bleeding or Exacerbated Diabetes and Impact of Multimorbidity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center of Competence Multimorbidity, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical practice guidelines do not take into account multimorbidity and various potential&#xD;
      therapeutic conflicts. Identifying and quantifying therapeutic conflicts is crucial in&#xD;
      multimorbid patients having more than two acute or chronic diseases. Guidance should be&#xD;
      available for frequent encountered situations, e.g. gastrointestinal bleeding or exacerbation&#xD;
      of diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study investigates multimorbidity in view of the occurrence of two different therapeutic&#xD;
      conflicts or dilemma situations, respectively. The first concerns patients with diagnosis of&#xD;
      gastrointestinal bleeding and prescription of anticoagulants or/and antiplatelet drugs (e.g.,&#xD;
      warfarin, clopidogrel and acetylsalicylic acid) as a risk factor for bleeding events. The&#xD;
      second concerns patients with diagnosis of exacerbated diabetes mellitus and prescription of&#xD;
      corticosteroids as a risk factor for worsening of blood glucose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients with gastrointestinal bleeding and anticoagulants or antiplatelet drugs</measure>
    <time_frame>5 years</time_frame>
    <description>Do anticoagulants or antiplatelet drugs increase the risk of repeated bleeding in patients with gastrointestinal bleeding?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients with diabetes mellitus and systemic corticosteroids</measure>
    <time_frame>5 years</time_frame>
    <description>Do systemic corticosteroids increase the risk of exacerbation in patients with diabetes mellitus?</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1101</enrollment>
  <condition>Gastrointestinal Hemorrhage</condition>
  <condition>Diabetes Complications</condition>
  <condition>Multimorbidity</condition>
  <arm_group>
    <arm_group_label>Multimorbid patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>drug-drug or drug-disease interaction</intervention_name>
    <arm_group_label>Multimorbid patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We investigate in the field of multimorbidity in a tertiary hospital regarding therapeutic&#xD;
        conflicts of GI bleeding and diabetes exacerbation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inpatients at the University Hospital Zurich, USZ&#xD;
&#xD;
          -  Male and female patients, aged 18 years or older&#xD;
&#xD;
          -  Fulfilling the criteria for Use Case A or B (i.e. patients with gastrointestinal&#xD;
             bleeding and anticoagulants or antiplatelet drugs, Use Case A or patients with&#xD;
             diabetes mellitus and/or systemic corticosteroids, Use Case B)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If potential participants have a statement in the electronic medical record or&#xD;
             elsewhere to refuse study participation, this represents exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edouard Battegay, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Zurich, Department of Internal Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klarissa Siebenhüner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Department of Internal Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Beeler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Zurich, Department of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multimorbidity</keyword>
  <keyword>multiple chronic conditions</keyword>
  <keyword>drug-drug interactions</keyword>
  <keyword>drug-disease interactions</keyword>
  <keyword>polypharmacy</keyword>
  <keyword>Oral anticoagulants</keyword>
  <keyword>Steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

